Recombinant
Showing 1 - 25 of 6,490
Bleeding Disorder Trial in Charlottesville (Recombinant von Willebrand Factor)
Not yet recruiting
- Bleeding Disorder
- Recombinant von Willebrand Factor
-
Charlottesville, VirginiaUVA Hospital
Nov 3, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Coronavirus Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel
Not yet recruiting
- Coronavirus
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Recombinant novel coronavirus protein vaccine (CHO cells)
- (no location specified)
Sep 5, 2023
Hepatic Ascites Trial in Guangdong (Recombinant Human Serum Albumin, Human serum albumin)
Not yet recruiting
- Hepatic Ascites
- Recombinant Human Serum Albumin
- Human serum albumin
-
Guangdong, Shenzhen, ChinaShenzhen Protgen Ltd
May 5, 2023
Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- (no location specified)
Sep 23, 2023
COVID-19 Trial (Recombinant variant COVID-19 vaccine (Sf9 cell), Recombinant COVID-19 vaccine (CHO cell), Recombinant COVID-19
Not yet recruiting
- COVID-19
- Recombinant variant COVID-19 vaccine (Sf9 cell)
- +2 more
- (no location specified)
Mar 10, 2023
COVID-19 Trial (Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19
Not yet recruiting
- COVID-19
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
- Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- (no location specified)
Jun 19, 2023
Vaccination; Infection, Vaccine Adverse Reaction Trial (Recombinant zoster vaccination)
Not yet recruiting
- Vaccination; Infection
- Vaccine Adverse Reaction
- Recombinant zoster vaccination
- (no location specified)
Jun 9, 2023
Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)
Enrolling by invitation
- Malignant Melanomas
- Recombinant Human Adenovirus Type 5 Injection
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023
Vaccine-Preventable Diseases, Herpes Zoster Trial in Zhenjiang (Recombinant Herpes Zoster Vaccine, Recombinant Herpes Zoster
Recruiting
- Vaccine-Preventable Diseases
- Herpes Zoster
- Recombinant Herpes Zoster Vaccine
- Recombinant Herpes Zoster Vaccine Placebo
-
Zhenjiang, Jiangsu, ChinaJiangsu Province Center for Disease Control and Prevention (Chin
Oct 12, 2023
Coronavirus Trial in Wuhu (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant
Active, not recruiting
- Coronavirus
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Recombinant novel coronavirus protein vaccine (CHO cells)
-
Wuhu, Anhui, ChinaWannan Medical College Yijishan Hospital
May 6, 2023
COVID-19 Trial (High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant
Not yet recruiting
- COVID-19
- High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
- +3 more
- (no location specified)
Jun 19, 2023
Herpes Zoster Trial in Makati City (REC610, Shingrix)
Recruiting
- Herpes Zoster
- REC610
- Shingrix
-
Makati City, Metro Manila, PhilippinesPharma Peak Research Philippines,Inc.
Mar 13, 2023
Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia Trial
Not yet recruiting
- Chronic Lung Disease of Prematurity
- +2 more
- Recombinant fragment of human surfactant protein D (rfhSP-D)
- (no location specified)
Jun 6, 2023
Herpes Zoster Trial in Xinxiang (Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster
Not yet recruiting
- Herpes Zoster
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
- +3 more
-
Xinxiang, Henan, ChinaYanjin Center for Disease Control and Prevention
May 4, 2023
Advanced Solid Tumors Trial in Hangzhou, Shanghai (Recombinant human IL-21 oncolytic vaccinia virus injection)
Not yet recruiting
- Advanced Solid Tumors
- Recombinant human IL-21 oncolytic vaccinia virus injection
-
Hangzhou, Zhejiang, China
- +1 more
Jun 21, 2023
Gastroenteritis Trial (Recombinant Norovirus Hexavalent Vaccine, Matching Placebo)
Not yet recruiting
- Gastroenteritis
- Recombinant Norovirus Hexavalent Vaccine
- Matching Placebo
- (no location specified)
Mar 27, 2023
COVID-19 Trial in Changsha (Recombinant Novel Coronavirus vaccine (CHO Cells))
Completed
- COVID-19
- Recombinant Novel Coronavirus vaccine (CHO Cells)
-
Changsha, Hunan, ChinaHunan Provincial Center for Disease Control and Prevention
Jun 6, 2023
Latent Tuberculosis Infection Trial (Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected)
Not yet recruiting
- Latent Tuberculosis Infection
- Recombinant Mycobacterium tuberculosis fusion protein for injection
- TB-PPD was injected
- (no location specified)
Feb 16, 2023
Herpes Zoster, Vaccine-Preventable Diseases Trial (Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant
Not yet recruiting
- Herpes Zoster
- Vaccine-Preventable Diseases
- Low Dose Recombinant Herpes Zoster Vaccine (LZ901)
- +2 more
- (no location specified)
Feb 28, 2023
Recurring Glioblastoma Trial in Fujian (Recombinant L-IFN adenovirus injection)
Recruiting
- Recurring Glioblastoma
- Recombinant L-IFN adenovirus injection
-
Fujian, Fujian, ChinaBinhai Hospital of Fujian Medical University
Jun 27, 2023
COVID-19 Trial (Recombinant variant COVID-19 vaccine(Sf9 cell))
Not yet recruiting
- COVID-19
- Recombinant variant COVID-19 vaccine(Sf9 cell)
- (no location specified)
Mar 10, 2023
Immunosuppression, COVID-19 Trial in Madison (NVX-CoV2372)
Not yet recruiting
- Immunosuppression
- COVID-19
- NVX-CoV2372
-
Madison, WisconsinUW School of Medicine and Public Health
Aug 31, 2023
COVID-19 Trial (1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for
Recruiting
- COVID-19
- 1 Nebulized inhalation for booster groups
- +23 more
-
Xiangxi, Hunan, ChinaCDC of of Luxi County, Xiangxi Tujia and Miao Autonomous Prefect
Oct 24, 2022
Norovirus Infections, Norwalk Gastroenteritis Trial (Human Norovirus Bivalent (G?.1/G?.4)Vaccine,Recombinant (Hansenula
Not yet recruiting
- Norovirus Infections
- Norwalk Gastroenteritis
- Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
- placebo
- (no location specified)
Jun 14, 2023